Carolyn Nessim

Dr. Carolyn Nessim's main research interests involve evaluating outcomes of cancer treatments using large databases for Melanoma, Soft Tissue Sarcoma, Gastric Cancer and Merkel Cell Carcinoma. Her other interests include understanding the immunology of Soft Tissue Sarcoma and Melanoma. She collaborates with scientists at OHRI doing translational projects looking at the role of oncolytic viruses, NK cells and T-cells in the treatment strategies for Sarcoma and Melanoma. She is the lead of the Research Evaluation Committee of the Trans-Atlantic Australasian Retro-Peritoneal Sarcoma Working Group (TARPSWG) and is a member of the Canadian Melanoma Research Network (CMRN). She is also an active member of the Ontario Cancer Research Ethics Board (OCREB) and the Chair for the Surveillance Subcommittee for Melanoma for the Canadian Cancer Trials Group (CCTG). 

Dr. Carolyn Nessim's main research interests involve understanding the immunology of Soft Tissue Sarcoma and Melanoma. She collaborates with scientists at OHRI doing translational projects looking at the role of oncolytic viruses, NK cells and T-cells in the treatment strategies for Sarcoma, GIST and Melanoma/Merkel Cell Carcinoma (MCC). Of particular interest, is identifying biomarkers of response to treatment. She has a particular interest in the evaluation of Liposarcomas as well as Unknown Primary Melanomas. She also leads and collaborates on many clinical research projects evaluating the treatment of Sarcoma/GIST and Melanoma/MCC. She is a member of the Trans-Atlantic Retro-Peritoneal Sarcoma Working Group (TARPSWG) and Global Melanoma Research Network (GMRN). She is also an active member of the Ontario Cancer Research Ethics Board (OCREB) and the Canadian Cancer Trials Group (CCTG).